From Charité Research to a Cologne-based fully integrated MedTech Company
History of the Company
LIMAA Technologies (LIght-sheet Microscopy and Automated Analysis) is a spin-off from the working group of Dr. Dr. René Hägerling from Charité – University Hospital in Berlin.
Registered office in Cologne; S1 and internal ISO 13485 audit
2025
Seed investment, BioCampus Cologne & Labor Becker partnership
2024
Technology transfer;
RUO commercial start
2022
LIMAA Technologies GmbH founded as a Charité spin-off
2021
EXIST funding launches translation
2014–2020
Scientific roots & clinical feasibility at Charité
2026
History of the Company
LIMAA Technologies (LIght-sheet Microscopy and Automated Analysis) is a spin-off from the working group of Dr. Dr. René Hägerling from Charité - University Hospital in Berlin.
René, with over a decade of experience in three-dimensional tissue analysis, initially focused on embryonic vascular development when faced with limitations in standard two-dimensional histology methods. He played a pivotal role in testing light-sheet microscopes from German startups and companies, pioneering spatial visualization of the vascular system.
During the 2014 Lindau Nobel Laureate Meeting, René met Dr. Fabian Mohr, who had transitioned from oncology research to strategy consulting and venture capital. Their collaboration began in 2017, aiming to apply light-sheet microscopy to clinical diagnostics. They garnered interest from private health insurers, particularly for diagnosing lymphedema and lipoedema, where clear tests were lacking.
After earning degrees in Chemistry, Human Medicine, and a PhD in Biology and Imaging as well a MD in 3D-Histology, René left the Max Planck Institute for Molecular Biomedicine in Münster for a residency at St. George’s University of London and the Charité - University Hospital in Berlin. There, he established his research group and continued developing light-sheet imaging-based diagnostics. In 2019, he entered the Berlin Institute of Health Digital Health Accelerator with Fabian. They evolved their concept into an automated platform for histopathology on entire tissue biopsies, departing from glass slide-based analyses.
In 2020, René and Fabian collaborated with Prof. Bruno Märkl from the University Hospital in Augsburg for a clinical feasibility study, yielding promising pilot data. In 2021, they secured EXIST funding to transform their scientific and clinical findings into products, marking the beginning of LIMAA Technologies. Subsequent support came from Prof. David Horst at Charité's Institute of Pathology, a European Research Council grants, and the establishment of LIMAA Technologies GmbH in 2022.
Get in Touch for More Information
If you are interested in learning more about our team, our technology and our vision feel free to reach out to us.